+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Intravenous Immunoglobulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 275 Pages
  • June 2025
  • Region: Global
  • Fairfield Market Research
  • ID: 5913388
The global intravenous immunoglobulin (IVIG) market is poised for remarkable growth, driven by rising incidences of immunodeficiency disorders and autoimmune diseases. According to the latest research analysis, the market is projected to reach a valuation of approximately US$ 16 billion by 2025 and is expected to expand further to over US$ 28 billion by 2032. This growth reflects a robust CAGR of 8.17% during the forecast period from 2022 to 2032. The increasing demand for effective therapies, especially in patients with chronic and rare immunological disorders, is anticipated to sustain this positive market trajectory.

Market Insights

Intravenous immunoglobulin therapy, primarily composed of pooled immunoglobulin G (IgG) antibodies derived from plasma donors, has become an essential treatment for patients suffering from primary and secondary immunodeficiency disorders. IVIG also plays a vital role in treating various autoimmune and inflammatory diseases. This therapy is increasingly being recognized as a critical component in managing life-threatening conditions where traditional treatments have limited effectiveness.

The market’s rapid development is also attributed to heightened awareness among healthcare providers and patients regarding the benefits of IVIG therapies. Additionally, advancements in diagnostic tools and improved healthcare infrastructure have made early diagnosis and intervention more feasible, thereby driving the overall treatment rate.

Key Market Drivers

Several key factors are driving the expansion of the intravenous immunoglobulin market:

  • Rising Prevalence of Immunodeficiency and Autoimmune Disorders: An increasing number of patients globally are diagnosed with conditions such as primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), Kawasaki disease, and hypogammaglobulinemia. These conditions necessitate regular IVIG therapy as part of long-term disease management.
  • Geriatric Population Growth: With aging populations across major economies, the incidence of immunological disorders is on the rise, thereby increasing the need for IVIG therapy in elderly patients.
  • Advancements in Plasma Collection and Processing: Enhanced technologies in plasma fractionation and antibody purification have improved the safety and efficacy profiles of IVIG products, encouraging greater adoption.
  • Increased FDA Approvals and R&D Activities: The surge in product approvals and continued investments by pharmaceutical giants into research and development have bolstered the pipeline for next-generation immunoglobulin therapies.

Business Opportunities

The intravenous immunoglobulin market holds promising opportunities, particularly in the areas of product development, distribution expansion, and clinical applications:

  • Off-Label Applications and Emerging Indications: Beyond FDA-approved uses, IVIG is increasingly being explored for off-label indications, including certain neurological and inflammatory disorders. This widens the therapeutic scope and presents avenues for clinical innovation.
  • Rising Healthcare Investment in Emerging Economies: Regions like Asia Pacific and Latin America are witnessing increased healthcare spending, regulatory reforms, and infrastructural advancements. These changes are opening new markets for IVIG providers and manufacturers.
  • Integration with Advanced Diagnostics: The combination of IVIG therapy with precise diagnostic methods is enhancing treatment outcomes, making it more appealing to healthcare professionals and institutions.

Regional Analysis

The intravenous immunoglobulin market exhibits varied performance across regions, with developed and developing markets both contributing to the growth:

  • North America: Holding a dominant position, North America accounts for a substantial share of the global market, led by the U.S. The high prevalence of immunodeficiency disorders, robust healthcare infrastructure, and a growing number of FDA-approved IVIG products are fueling demand.
  • Asia Pacific: This region is expected to witness significant growth over the coming years, attributed to increased patient awareness, growing geriatric population, and an uptick in diagnosed immune-related conditions. The rising investment in healthcare systems across China, India, and Southeast Asia is likely to drive future market expansion.
  • Europe: With established healthcare frameworks and strong reimbursement systems, Europe continues to be a key market. Increasing clinical trials and improved access to therapies are contributing to steady growth.
  • Latin America and Middle East & Africa: These regions present untapped potential, especially with the expansion of healthcare services and the rising demand for specialized treatments.

Key Players

The intravenous immunoglobulin market is moderately consolidated, with several major players actively contributing to innovation, manufacturing, and global distribution. Strategic collaborations, mergers, and acquisitions have been pivotal in shaping the competitive Analysis.

Prominent players in the global IVIG market include:

  • Biotest AG
  • Baxter International Inc.
  • Octopharma AG
  • LFB Biotechnologies
  • Grifols SA
  • Argenx
  • CSL Behring
  • China Biologics Products Inc.
  • Kedrian Biopharma
  • BDI Pharma Inc.
  • Pfizer Inc.
These companies are investing in expanding their plasma collection networks, enhancing product lines, and exploring newer clinical applications for IVIG therapies.

Recent Industry Developments

  • In February 2021, Pfizer received U.S. FDA approval for PANZYGA, an IVIG product for treating adults with CIDP.
  • In April 2022, Grifols S.A. completed the acquisition of Biotest AG, bolstering its position in the global immunoglobulin market by enhancing its production capabilities and market reach.

Market Segmentation

By Type:

  • IgG
  • IgM
  • IgA
  • IgE
  • IgD

By Application:

  • Hypogammaglobulinemia
  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Immunodeficiency Diseases
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy
  • Idiopathic Thrombocytopenic Purpura
  • Inflammatory Myopathies
  • Specific Antibody Deficiency
  • Guillain-Barre Syndrome
  • Others

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

By End User:

  • Hospitals
  • Specialty Clinics
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Intravenous Immunoglobulin Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Intravenous Immunoglobulin Market Outlook, 2019-2032
3.1. Global Intravenous Immunoglobulin Market Outlook, by Type, Value (US$ Bn), 2019-2032
3.1.1. Key Highlights
3.1.1.1. IgG
3.1.1.2. IgM
3.1.1.3. IgA
3.1.1.4. IgE
3.1.1.5. IgD
3.2. Global Intravenous Immunoglobulin Market Outlook, by Application, Value (US$ Bn), 2019-2032
3.2.1. Key Highlights
3.2.1.1. Hypogammaglobulinemia
3.2.1.2. Chronic Inflammatory Demyelinating Polyneuropathy
3.2.1.3. Immunodeficiency Diseases
3.2.1.4. Myasthenia Gravis
3.2.1.5. Multifocal Motor Neuropathy
3.2.1.6. Idiopathic Thrombocytopenic Purpura
3.2.1.7. Inflammatory Myopathies
3.2.1.8. Specific Antibody Deficiency
3.2.1.9. Guillain-Barre Syndrome
3.2.1.10. Others
3.3. Global Intravenous Immunoglobulin Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
3.3.1. Key Highlights
3.3.1.1. Hospital Pharmacy
3.3.1.2. Retail Pharmacy
3.3.1.3. Others
3.4. Global Intravenous Immunoglobulin Market Outlook, by End User, Value (US$ Bn), 2019-2032
3.4.1. Key Highlights
3.4.1.1. Hospitals
3.4.1.2. Specialty Clinics
3.4.1.3. Others
3.5. Global Intravenous Immunoglobulin Market Outlook, by Region, Value (US$ Bn), 2019-2032
3.5.1. Key Highlights
3.5.1.1. North America
3.5.1.2. Europe
3.5.1.3. Asia Pacific
3.5.1.4. Latin America
3.5.1.5. Middle East & Africa
4. North America Intravenous Immunoglobulin Market Outlook, 2019-2032
4.1. North America Intravenous Immunoglobulin Market Outlook, by Type, Value (US$ Bn), 2019-2032
4.1.1. Key Highlights
4.1.1.1. IgG
4.1.1.2. IgM
4.1.1.3. IgA
4.1.1.4. IgE
4.1.1.5. IgD
4.2. North America Intravenous Immunoglobulin Market Outlook, by Application, Value (US$ Bn), 2019-2032
4.2.1. Key Highlights
4.2.1.1. Hypogammaglobulinemia
4.2.1.2. Chronic Inflammatory Demyelinating Polyneuropathy
4.2.1.3. Immunodeficiency Diseases
4.2.1.4. Myasthenia Gravis
4.2.1.5. Multifocal Motor Neuropathy
4.2.1.6. Idiopathic Thrombocytopenic Purpura
4.2.1.7. Inflammatory Myopathies
4.2.1.8. Specific Antibody Deficiency
4.2.1.9. Guillain-Barre Syndrome
4.2.1.10. Others
4.3. North America Intravenous Immunoglobulin Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
4.3.1. Key Highlights
4.3.1.1. Hospital Pharmacy
4.3.1.2. Retail Pharmacy
4.3.1.3. Others
4.4. North America Intravenous Immunoglobulin Market Outlook, by End User, Value (US$ Bn), 2019-2032
4.4.1. Key Highlights
4.4.1.1. Hospitals
4.4.1.2. Specialty Clinics
4.4.1.3. Others
4.5. North America Intravenous Immunoglobulin Market Outlook, by Country, Value (US$ Bn), 2019-2032
4.5.1. Key Highlights
4.5.1.1. U.S. Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
4.5.1.2. U.S. Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
4.5.1.3. U.S. Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
4.5.1.4. U.S. Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
4.5.1.5. Canada Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
4.5.1.6. Canada Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
4.5.1.7. Canada Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
4.5.1.8. Canada Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
4.5.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Intravenous Immunoglobulin Market Outlook, 2019-2032
5.1. Europe Intravenous Immunoglobulin Market Outlook, by Type, Value (US$ Bn), 2019-2032
5.1.1. Key Highlights
5.1.1.1. IgG
5.1.1.2. IgM
5.1.1.3. IgA
5.1.1.4. IgE
5.1.1.5. IgD
5.2. Europe Intravenous Immunoglobulin Market Outlook, by Application, Value (US$ Bn), 2019-2032
5.2.1. Key Highlights
5.2.1.1. Hypogammaglobulinemia
5.2.1.2. Chronic Inflammatory Demyelinating Polyneuropathy
5.2.1.3. Immunodeficiency Diseases
5.2.1.4. Myasthenia Gravis
5.2.1.5. Multifocal Motor Neuropathy
5.2.1.6. Idiopathic Thrombocytopenic Purpura
5.2.1.7. Inflammatory Myopathies
5.2.1.8. Specific Antibody Deficiency
5.2.1.9. Guillain-Barre Syndrome
5.2.1.10. Others
5.3. Europe Intravenous Immunoglobulin Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
5.3.1. Key Highlights
5.3.1.1. Hospital Pharmacy
5.3.1.2. Retail Pharmacy
5.3.1.3. Others
5.4. Europe Intravenous Immunoglobulin Market Outlook, by End User, Value (US$ Bn), 2019-2032
5.4.1. Key Highlights
5.4.1.1. Hospitals
5.4.1.2. Specialty Clinics
5.4.1.3. Others
5.5. Europe Intravenous Immunoglobulin Market Outlook, by Country, Value (US$ Bn), 2019-2032
5.5.1. Key Highlights
5.5.1.1. Germany Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
5.5.1.2. Germany Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
5.5.1.3. Germany Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.5.1.4. Germany Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
5.5.1.5. U.K. Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
5.5.1.6. U.K. Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
5.5.1.7. U.K. Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.5.1.8. U.K. Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
5.5.1.9. France Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
5.5.1.10. France Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
5.5.1.11. France Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.5.1.12. France Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
5.5.1.13. Italy Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
5.5.1.14. Italy Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
5.5.1.15. Italy Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.5.1.16. Italy Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
5.5.1.17. Turkey Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
5.5.1.18. Turkey Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
5.5.1.19. Turkey Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.5.1.20. Turkey Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
5.5.1.21. Russia Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
5.5.1.22. Russia Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
5.5.1.23. Russia Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.5.1.24. Russia Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
5.5.1.25. Rest of Europe Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
5.5.1.26. Rest of Europe Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
5.5.1.27. Rest of Europe Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.5.1.28. Rest of Europe Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
5.5.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Intravenous Immunoglobulin Market Outlook, 2019-2032
6.1. Asia Pacific Intravenous Immunoglobulin Market Outlook, by Type, Value (US$ Bn), 2019-2032
6.1.1. Key Highlights
6.1.1.1. IgG
6.1.1.2. IgM
6.1.1.3. IgA
6.1.1.4. IgE
6.1.1.5. IgD
6.2. Asia Pacific Intravenous Immunoglobulin Market Outlook, by Application, Value (US$ Bn), 2019-2032
6.2.1. Key Highlights
6.2.1.1. Hypogammaglobulinemia
6.2.1.2. Chronic Inflammatory Demyelinating Polyneuropathy
6.2.1.3. Immunodeficiency Diseases
6.2.1.4. Myasthenia Gravis
6.2.1.5. Multifocal Motor Neuropathy
6.2.1.6. Idiopathic Thrombocytopenic Purpura
6.2.1.7. Inflammatory Myopathies
6.2.1.8. Specific Antibody Deficiency
6.2.1.9. Guillain-Barre Syndrome
6.2.1.10. Others
6.3. Asia Pacific Intravenous Immunoglobulin Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
6.3.1. Key Highlights
6.3.1.1. Hospital Pharmacy
6.3.1.2. Retail Pharmacy
6.3.1.3. Others
6.4. Asia Pacific Intravenous Immunoglobulin Market Outlook, by End User, Value (US$ Bn), 2019-2032
6.4.1. Key Highlights
6.4.1.1. Hospitals
6.4.1.2. Specialty Clinics
6.4.1.3. Others
6.5. Asia Pacific Intravenous Immunoglobulin Market Outlook, by Country, Value (US$ Bn), 2019-2032
6.5.1. Key Highlights
6.5.1.1. China Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
6.5.1.2. China Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
6.5.1.3. China Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.5.1.4. China Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
6.5.1.5. Japan Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
6.5.1.6. Japan Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
6.5.1.7. Japan Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.5.1.8. Japan Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
6.5.1.9. South Korea Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
6.5.1.10. South Korea Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
6.5.1.11. South Korea Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.5.1.12. South Korea Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
6.5.1.13. India Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
6.5.1.14. India Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
6.5.1.15. India Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.5.1.16. India Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
6.5.1.17. Southeast Asia Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
6.5.1.18. Southeast Asia Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
6.5.1.19. Southeast Asia Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.5.1.20. Southeast Asia Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
6.5.1.21. Rest of Asia Pacific Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
6.5.1.22. Rest of Asia Pacific Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
6.5.1.23. Rest of Asia Pacific Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.5.1.24. Rest of Asia Pacific Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Intravenous Immunoglobulin Market Outlook, 2019-2032
7.1. Latin America Intravenous Immunoglobulin Market Outlook, by Type, Value (US$ Bn), 2019-2032
7.1.1. Key Highlights
7.1.1.1. IgG
7.1.1.2. IgM
7.1.1.3. IgA
7.1.1.4. IgE
7.1.1.5. IgD
7.2. Latin America Intravenous Immunoglobulin Market Outlook, by Application, Value (US$ Bn), 2019-2032
7.2.1.1. Hypogammaglobulinemia
7.2.1.2. Chronic Inflammatory Demyelinating Polyneuropathy
7.2.1.3. Immunodeficiency Diseases
7.2.1.4. Myasthenia Gravis
7.2.1.5. Multifocal Motor Neuropathy
7.2.1.6. Idiopathic Thrombocytopenic Purpura
7.2.1.7. Inflammatory Myopathies
7.2.1.8. Specific Antibody Deficiency
7.2.1.9. Guillain-Barre Syndrome
7.2.1.10. Others
7.3. Latin America Intravenous Immunoglobulin Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
7.3.1. Key Highlights
7.3.1.1. Hospital Pharmacy
7.3.1.2. Retail Pharmacy
7.3.1.3. Others
7.4. Latin America Intravenous Immunoglobulin Market Outlook, by End User, Value (US$ Bn), 2019-2032
7.4.1. Key Highlights
7.4.1.1. Hospitals
7.4.1.2. Specialty Clinics
7.4.1.3. Others
7.5. Latin America Intravenous Immunoglobulin Market Outlook, by Country, Value (US$ Bn), 2019-2032
7.5.1. Key Highlights
7.5.1.1. Brazil Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
7.5.1.2. Brazil Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
7.5.1.3. Brazil Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.5.1.4. Brazil Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
7.5.1.5. Mexico Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
7.5.1.6. Mexico Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
7.5.1.7. Mexico Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.5.1.8. Mexico Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
7.5.1.9. Argentina Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
7.5.1.10. Argentina Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
7.5.1.11. Argentina Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.5.1.12. Argentina Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
7.5.1.13. Rest of Latin America Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
7.5.1.14. Rest of Latin America Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
7.5.1.15. Rest of Latin America Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.5.1.16. Rest of Latin America Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Intravenous Immunoglobulin Market Outlook, 2019-2032
8.1. Middle East & Africa Intravenous Immunoglobulin Market Outlook, by Type, Value (US$ Bn), 2019-2032
8.1.1. Key Highlights
8.1.1.1. IgG
8.1.1.2. IgM
8.1.1.3. IgA
8.1.1.4. IgE
8.1.1.5. IgD
8.2. Middle East & Africa Intravenous Immunoglobulin Market Outlook, by Application, Value (US$ Bn), 2019-2032
8.2.1. Key Highlights
8.2.1.1. Hypogammaglobulinemia
8.2.1.2. Chronic Inflammatory Demyelinating Polyneuropathy
8.2.1.3. Immunodeficiency Diseases
8.2.1.4. Myasthenia Gravis
8.2.1.5. Multifocal Motor Neuropathy
8.2.1.6. Idiopathic Thrombocytopenic Purpura
8.2.1.7. Inflammatory Myopathies
8.2.1.8. Specific Antibody Deficiency
8.2.1.9. Guillain-Barre Syndrome
8.2.1.10. Others
8.3. Middle East & Africa Intravenous Immunoglobulin Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
8.3.1. Key Highlights
8.3.1.1. Hospital Pharmacy
8.3.1.2. Retail Pharmacy
8.3.1.3. Others
8.4. Middle East & Africa Intravenous Immunoglobulin Market Outlook, by End User, Value (US$ Bn), 2019-2032
8.4.1. Key Highlights
8.4.1.1. Hospitals
8.4.1.2. Specialty Clinics
8.4.1.3. Others
8.5. Middle East & Africa Intravenous Immunoglobulin Market Outlook, by Country, Value (US$ Bn), 2019-2032
8.5.1. Key Highlights
8.5.1.1. GCC Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
8.5.1.2. GCC Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
8.5.1.3. GCC Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.5.1.4. GCC Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
8.5.1.5. South Africa Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
8.5.1.6. South Africa Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
8.5.1.7. South Africa Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.5.1.8. South Africa Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
8.5.1.9. Egypt Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
8.5.1.10. Egypt Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
8.5.1.11. Egypt Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.5.1.12. Egypt Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
8.5.1.13. Nigeria Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
8.5.1.14. Nigeria Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
8.5.1.15. Nigeria Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.5.1.16. Nigeria Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
8.5.1.17. Rest of Middle East & Africa Intravenous Immunoglobulin Market by Type, Value (US$ Bn), 2019-2032
8.5.1.18. Rest of Middle East & Africa Intravenous Immunoglobulin Market by Application, Value (US$ Bn), 2019-2032
8.5.1.19. Rest of Middle East & Africa Intravenous Immunoglobulin Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.5.1.20. Rest of Middle East & Africa Intravenous Immunoglobulin Market by End User, Value (US$ Bn), 2019-2032
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. by Distribution Channel vs by Application Heatmap
9.2. Manufacturer vs by Application Heatmap
9.3. Company Market Share Analysis, 2025
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Biotest AG
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Baxter International Inc.
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Octapharma AG
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. LFB Biotechnologies
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Grifols SA
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. CSL Behring
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. China Biologics Products Inc.
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Kedrion Biopharma
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. BDI Pharma Inc.
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Pfizer Inc.
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

  • Biotest AG
  • Baxter International Inc.
  • Octapharma AG
  • LFB Biotechnologies
  • Grifols SA
  • CSL Behring
  • China Biologics Products Inc.
  • Kedrion Biopharma
  • BDI Pharma Inc.
  • Pfizer Inc.